An Audience With in 2011

Filter By:

Article Type
Year

  • Marc Kirschner, Chairman of Harvard Medical School's Department of Systems Biology, discusses Harvard's new Initiative in Systems Pharmacology.

    An Audience With

  • David Urdal, Chief Scientific Officer at Dendreon, discusses his 30-year experience in industry ahead of his retirement later this year.

    An Audience With

  • Paul Brown, CEO of Roche Molecular Diagnostics, discusses the regulatory and reimbursement concerns that challenge the success of companion diagnostics.

    An Audience With

  • Joe Selby, the newly appointed Executive Director of the Patient-Centered Outcomes Research Institute (PCORI), discusses the agenda for the new federally-mandated comparative effectiveness research-focused organization.

    An Audience With

  • Robert Dworkin, Director of ACTION, discusses the public–private partnership's plans to revamp clinical trial design for pain drugs.

    An Audience With

  • Alan Aderem, recently appointed Director of Seattle BioMed, discusses the promise of systems biology for infectious disease.

    An Audience With

  • Richard Bergström, the newly appointed Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), discusses his plans for restoring Europe's drug R&D competitiveness.

    An Audience With

  • Fergus Sweeney, Head of Compliance and Inspection Sector at the European Medicines Agency, discusses the strengths and weaknesses of the new EU Clinical Trials Register.

    An Audience With

  • Nic Jones, the recently appointed Chief Scientist of the charity Cancer Research UK (CRUK), speaks about the current state of basic cancer biology research and exciting developments in oncology.

    An Audience With

  • Susan Desmond-Hellmann, Chancellor of the University of California, San Francisco and former President of Product Development at Genentech, discusses industry's increasing interest in collaborating with academia.

    An Audience With

  • Abraham Thomas, panellist at three US Food and Drug Administration (FDA) hearings on new potential anti-obesity agents last year, discusses the need for change in the agency's anti-obesity regulatory guidelines.

    An Audience With